Urol. praxi, 2011; 12(3): 147-151

Treatment of non-neurogenic voiding dysfunction in men

MUDr.Květoslav Novák, FEBU
Urologická klinika 1. LF UK a VFN, Praha

Treatment of non-neurogenic voiding dysfunction in men is focused on lower urinary tract symptoms. Their prevalence increases with

age concernig men with bening prostatic hyperplasia and overactive bladder. The most frequently used drug-groups are α-blockers,

5α-reductase inhibitors and antimuscarinics. Combined therapy have a special indications – are explained in overview.

Keywords: lower urinary tract symptoms, benign prostatic hyperplasia, overactive bladder

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novák K. Treatment of non-neurogenic voiding dysfunction in men. Urol. praxi. 2011;12(3):147-151.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Oelke M, Bachmann A, Descazeaud A, et al. Gudelines on conservative treatment of non-neurogenic male LUTS. In: European Association of Urology Guidelines, 2010 edition.
    2. Nickel JC. BHP: Cost and treatment outcome. Am J Manag Care 2006; 12: 141-148.
    3. Malmsten UGH, Molander U, Peeker R, et al. Urinary incontinence, overactive bladder, and other urinary tract symptoms: A longitudinal population-based survey in men aged 45-103 years. Eur Urol 2010; 58: 149-156. Go to original source... Go to PubMed...
    4. Helfand BT, Evans RM, McVary K. A comparison of the frequencies of medical therapies for overactive bladder in men and women: Analysis of more than 7,2 million aging patiens. Eur Urol 2010; 57: 586-591. Go to original source... Go to PubMed...
    5. Michel M, de la Rosette J. Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Eur Urol. 2009; Suppl 8: 496-503. Go to original source...
    6. Gravas S, Melekos MD. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment? Curr Opin Urol 2009; 19: 49-54. Go to original source... Go to PubMed...
    7. Barendrecht MM, Abrams P, Schumacher H, et al. Do ?1-adrenoreceptors antagonists improve lower urinary tract symptoms by reducing bladder outlet resistence? Neurol Urodyn 2008; 27: 226-230. Go to original source... Go to PubMed...
    8. Kortmann BBM, Floratos DL, Kiemeney LAML, et al. Urodynamic effect of alpha-adrenoreceptor blockers: a review of clinical trials. Urology 2003; 62: 1-9. Go to original source... Go to PubMed...
    9. Hutchinson A, Farmer R, Verhamme K, et al. The efficacy of drugs for the treatment of LUTS/BHP, a study in 6 European countries. Eur Urol 2007; 51(1): 207-215. Go to original source... Go to PubMed...
    10. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007; 29(3): 387-398. Go to original source... Go to PubMed...
    11. Sobotka R, Hanuš T, Novák K. Hyperaktivní močový měchýř u dětí a dospělých. Urol List 2010; 8(3): 83-88.
    12. Roehrborn C G, Siami P, Barkin J, et al. The influence of baseline parameters on changes in International prostate symptom score with dutasteride, tamsulosin and combination therapy in men with symptomatic benign prostatic hyperplasia and enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55: 461-471. Go to original source... Go to PubMed...
    13. Armitage J, Emberton M. The role of anticholinergic drugs in men lower urinary tract symptoms. Curr Opin Urol 2008; 18: 11-15. Go to original source... Go to PubMed...
    14. Roehrborn CG, Kaplan SA, Jones JS, et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: Effect of prostate size. Eur Urol 2009; 55: 472-481. Go to original source... Go to PubMed...
    15. Kaplan SA, Roehrborn CG, Rovnej ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 15: 296(19): 2319-2328. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.